Lung Cancer

Lung cancer is the leading cause of cancer death worldwide.

Non-small cell lung cancer, or NSCLC, accounts for roughly 85% of cases.

Urolithin A has now been studied across several NSCLC models, including A549, H460, and H1975.

That coverage matters.

It includes KRAS-mutant settings, p53-intact settings, and an EGFR-mutant resistant setting.

The lung-cancer literature is still fully preclinical.

There are no published clinical trials of Urolithin A in lung-cancer patients.

Overview of the evidence

The current lung-cancer evidence is stronger than a simple one-study signal.

Several independent groups have described anti-lung-cancer effects through different mechanisms.

Those mechanisms do not all point in the same direction biologically.

That is useful.

It suggests the activity is not dependent on a single fragile pathway.

The strongest current themes are:

• EMT inhibition through the p53/MDM2/Snail axis

• PI3K/AKT/mTOR suppression with autophagy induction

• degradation of the actin-regulatory protein TMSB10 with impaired migration and invasion

One of these studies also includes in vivo xenograft validation.

That makes lung cancer one of the more credible non-gastrointestinal settings for Urolithin A.

EMT inhibition through the p53/MDM2/Snail axis

This is the best-characterised Urolithin-A-specific mechanism in lung cancer.

It was described in 2021 using A549 and H460 cells.

EMT, or epithelial-mesenchymal transition, is one of the main ways lung-cancer cells become more invasive.

It helps drive migration, local spread, distant metastasis, and treatment resistance.

A central EMT regulator in this work was Snail.

Snail represses E-cadherin and supports a more mesenchymal phenotype.

Urolithin A disrupted the interaction between p53 and MDM2.

That matters for two reasons.

First, it stabilised p53.

Second, it promoted Snail ubiquitination and degradation.

The same p53/MDM2 disruption also appears on the Prostate Cancer page.

That makes this look like a recurring cross-cancer mechanism rather than an isolated cell-line effect.

The downstream consequences were consistent with EMT reversal:

• higher E-cadherin expression

• lower vimentin expression

• lower N-cadherin expression

• reduced migration in scratch assays

• reduced invasion in Matrigel transwell assays

Snail knockdown experiments strengthened the mechanism.

When Snail was already depleted, Urolithin A produced additional epithelial-shift effects.

That supports Snail as a real functional node rather than a bystander marker.

PI3K/AKT/mTOR suppression and autophagy induction

A 2025 study extended the lung-cancer story into an EGFR-mutant resistant model.

It used H1975 cells, which carry the EGFR L858R and T790M mutations.

That is a clinically relevant resistance setting in NSCLC.

Urolithin A suppressed H1975 proliferation in a dose-dependent and time-dependent way.

Transcriptomic analysis pointed to PI3K/AKT/mTOR inhibition as the main pathway response.

Downstream, Urolithin A induced autophagy, with increased LC3-II and reduced mTOR-pathway signalling.

This fits a broader pattern already seen for Urolithin A in other cancer types.

Autophagy-linked activity also appears on the Pancreatic Cancer, Colorectal Cancer, and Glioblastoma pages.

That consistency makes the lung finding more credible.

In vivo xenograft validation

This same study also provides the only published in vivo lung-cancer evidence for Urolithin A so far.

In H1975 xenograft-bearing mice, Urolithin A supplementation significantly reduced tumour growth compared with vehicle control.

Tumour tissue showed enhanced autophagy and lower mTOR-pathway signalling.

That means the proposed mechanism did not stay confined to cell culture.

It also operated in tumour tissue in vivo.

Gut-lung-axis signal

The xenograft study added another layer.

It also examined gut microbiota changes after Urolithin A supplementation.

16S rRNA analysis showed a shift in microbial composition, including:

• higher Lactobacillus

• lower Desulfovibrio

Those microbial changes correlated with altered autophagy-related gene expression in tumour tissue.

That does not prove the microbiome change caused the anti-tumour effect.

The evidence is correlative.

Even so, it is a plausible finding.

Urolithin A is tightly linked to postbiotic biology, and lung immunity is influenced by gut-derived inflammatory and metabolic signals.

So the gut-lung-axis hypothesis is worth tracking.

TMSB10 degradation and F-actin disruption

A 2024 proteomics study identified a third lung-cancer mechanism.

This one focused on cell motility rather than EMT or mTOR signalling.

Using A549 cells, the study found broad proteomic remodelling after Urolithin A exposure.

The most important hit was TMSB10, or thymosin beta-10.

TMSB10 is an actin-regulatory protein that is often overexpressed in cancer.

In this context, Urolithin A promoted TMSB10 degradation through the autophagy-lysosome pathway.

It did not mainly act by lowering TMSB10 transcription.

It increased protein degradation.

That disrupted actin dynamics and impaired F-actin formation at membrane protrusions.

The functional result was lower migration and invasion capacity.

TMSB10 knockdown reproduced much of the same phenotype.

That makes this a mechanistically specific finding rather than a generic proteomics association.

It also suggests Urolithin A may suppress lung-cancer motility through at least two independent routes:

• EMT reversal through Snail depletion

• cytoskeletal disruption through TMSB10 degradation

Why the subtype coverage matters

The current studies span more than one important NSCLC context.

A549 and H460 represent KRAS-mutant disease.

H1975 represents EGFR-mutant disease with the T790M resistance mutation.

That matters because KRAS-mutant and EGFR-mutant resistant NSCLC are two of the most clinically important difficult-to-treat settings.

The literature still does not cover everything.

There is no direct Urolithin A work yet in squamous NSCLC, ALK-rearranged disease, or ROS1-rearranged disease.

Even so, the existing subtype spread is better than a single-line dataset.

One obvious unanswered question is whether Urolithin A affects sensitivity to osimertinib or other EGFR-targeted drugs.

The H1975 data make that a logical next step.

It has not yet been tested directly.

FOXO1 and CD8-positive T-cell surveillance

Urolithin A has also been linked to FOXO1 activation in CD8-positive T cells.

That broader immune-surveillance biology is discussed on the Immune Effects page.

This has not yet been tested directly in lung-cancer models.

Still, it is relevant.

CD8-positive T-cell infiltration is an important prognostic feature in NSCLC and often matters for checkpoint-inhibitor response.

So this is a plausible extension of the current lung-cancer story, not yet a demonstrated one.

What remains unknown

Several gaps still matter.

• no clinical trials in lung-cancer patients

• no direct study yet in lung squamous-cell carcinoma

• no published combination data with osimertinib, erlotinib, or other EGFR inhibitors

• no published combination data with PD-1 or PD-L1 blockade in lung-cancer models

• no proof that microbiome remodelling is the cause of tumour suppression rather than a parallel effect

• no data yet in ALK-rearranged or ROS1-rearranged NSCLC

Bottom line

Lung cancer is now one of the more interesting Urolithin A evidence areas outside the gastrointestinal setting.

That conclusion rests on several strengths:

• multiple independent mechanistic studies

• coverage across both KRAS-mutant and EGFR-mutant resistant NSCLC models

• repeated migration and invasion suppression

• a validated EMT mechanism through p53/MDM2/Snail

• in vivo xenograft evidence with PI3K/AKT/mTOR-linked autophagy findings

• a newer gut-lung-axis hypothesis that may help explain part of the in vivo effect

The evidence is still fully preclinical.

Even so, the lung-cancer signal looks biologically coherent and increasingly difficult to dismiss as a one-off finding.

References

Urolithin A inhibits epithelial-mesenchymal transition in lung cancer via the p53/MDM2 pathway to regulate Snail expression
https://pmc.ncbi.nlm.nih.gov/articles/PMC8139733/

Dietary Urolithin A suppresses lung cancer via gut microbiota-mediated autophagy activation
https://pubmed.ncbi.nlm.nih.gov/40849021/

Urolithin A promotes the degradation of TMSB10 to deform F-actin and inhibit NSCLC cell migration and invasion
https://pubmed.ncbi.nlm.nih.gov/39368341/

Unveiling the potential of Urolithin A in cancer therapy — mechanistic insights to future perspectives
https://pmc.ncbi.nlm.nih.gov/articles/PMC12188533/

A potential dietary intervention to improve T cell surveillance for cancer — Urolithin A promotes CD8-positive T-cell-mediated cancer immunosurveillance via FOXO1 activation
https://www.ludwigcancerresearch.org/ludwig-link/september-2024/a-potential-dietary-intervention-to-improve-t-cell-surveillance-for-cancer